Dysosmobacter welbionis 中新型肌醇至丁酸发酵通路及其与代谢和肝脏健康的关联
Dysosmobacter welbionis 是一种产丁酸肠道菌,其丰度与代谢健康改善相关。研究分析人群队列发现该菌在 MASLD 中减少且与纤维化评分负相关,并在高脂饮食小鼠中改善血糖和肝脂肪变性;结合同位素标记、基因组与蛋白组学,鉴定出一条非经典肌醇至丁酸发酵通路。
要点
- D. welbionis 及 D. hominis、D. segnis 是人类肠道常见菌。
- D. welbionis 丰度在 MASLD 中降低,并与纤维化评分负相关。
- D. welbionis J115T 改善高脂饮食小鼠血糖和肝脂肪变性。
核心结论
- D. welbionis 具有独特且保守的肌醇至丁酸发酵通路,支持其作为改善代谢和肝脏健康的下一代益生菌潜力。
研究设计与样本
- 分析多个人类队列以评估与肝脏健康的关联,并在饮食诱导脂肪变性小鼠模型中评估 D. welbionis J115T 补充效果。
- 采用抗体引导的厌氧细胞分选策略分离不同菌株,结合 13C 标记肌醇同位素与 NMR、质谱、基因组学和蛋白质组学进行研究。
主要发现
- D. welbionis 和两个相关物种 D. hominis、D. segnis 是人类肠道常见细菌。
- 在两个队列中 D. welbionis 丰度在 MASLD 中降低,在第三个队列中与纤维化评分呈负相关。
- D. welbionis J115T 治疗改善了高脂饮食喂养小鼠的血糖和肝脂肪变性。
- 鉴定出一条非经典肌醇至丁酸发酵通路。
- 分离出 19 株人类菌株,23 株比较基因组学显示开放泛基因组(约 2100 个核心基因),包含完整的肌醇发酵通路。
临床怎么用
- D. welbionis 丰度降低与 MASLD 及纤维化评分负相关,提示其作为代谢和肝脏健康生物标志物的潜在价值。
- D. welbionis J115T 在动物模型中改善血糖和肝脂肪变性,支持进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysosmobacter welbionis is a recently discovered butyrate producer whose presence in stool correlates with improved metabolic health. Whether its abundance is reduced in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unknown. Mechanistic insight into its butyrate production from myo-inositol, a dietary compound from fruits, beans, grains and nuts with metabolic benefits, is also limited. OBJECTIVE: To assess population-level distribution, relative abundance and strain diversity of D. welbionis in humans, and to elucidate its metabolic capacity to ferment myo-inositol into butyrate. DESIGN: We analysed several human cohorts for associations with liver health and evaluated D. welbionis J115T supplementation in a diet-induced steatosis mouse model. An antibody-guided anaerobic cell-sorting strategy enabled isolation of distinct strains. We combined 13C-labelled inositol isotopes with NMR, mass spectrometry, genomics and proteomics. RESULTS: We found that D. welbionis and two related species (D. hominis and D. segnis) are prevalent gut bacteria in the human gut. D. welbionis abundance was reduced in MASLD across two cohorts and inversely correlated with fibrosis score in a third cohort. Treatment with D. welbionis J115T improved glycaemia and hepatic steatosis in high-fat diet fed mice. We identified a non-canonical myo-inositol-to-butyrate fermentation pathway. 19 human strains were isolated, comparative genomics of 23 strains revealed an open pangenome (about 2100 core genes) including the full myo-inositol fermentation pathway. CONCLUSION: D. welbionis possesses a unique, conserved route to convert dietary myo-inositol into butyrate, distinguishing it from other commensals and supporting its potential as a next-generation probiotic for metabolic and liver health.
引用
- Lee CH, Bui TPN, Petitfils C, et al. Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health. Gut. 2026. PMID: 41500802. doi:10.1136/gutjnl-2025-336617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。